MARIETTA, Ga., April 18, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that Dr. Mark Landy, Vice President – Strategic Initiatives, will represent the Company at the 5th Annual Cell & Gene Therapy Investor Day in Boston, Massachusetts. The presentation will be conducted "investor conference" style, with a 5-minute introduction by the presenter, followed by a 10 minute "fireside chat" discussion on stage with a leading research analyst. The MiMedx timeslot is scheduled for Thursday, April 27, at 8:55 a.m. eastern time, at The State Room, Boston, Massachusetts. A webcast of this presentation will be available on the Company's website, www.mimedx.com
About ARM's Cell & Gene Therapy Investor Day
Organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray, this one-day, high impact program provides institutional, strategic and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools. The event includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how cell and gene therapies could impact the standard of care in key therapeutic areas such as cardiovascular disease, wound healing and tissue repair, ophthalmology, neurodegenerative diseases, diabetes and oncology. The program will include talks by key opinion leaders in the industry, life science investment experts and analysts covering the sector as well as presentations by more than 30 leading companies from across the globe.
MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biopharmaceutical and biomaterial products processed from donated placental tissues. "Innovations in Regenerative Medicine" is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of placental tissue, having supplied over 800,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mimedx-to-present-at-5th-annual-cell--gene-therapy-investor-day-300441074.html
SOURCE MiMedx Group, Inc.
Investor Contact: COCKRELL GROUP, Rich Cockrell, 877-889-1972, firstname.lastname@example.org, cockrellgroup.com; Contact: Michael Senken, Phone: (770) 651-9100